Biopharma | June 29, 2025
Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France
Extended lab space for product development, customer demos, and training
Extended lab space for product development, customer demos, and training
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The inspection concluded with zero Form 483 observations
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Subscribe To Our Newsletter & Stay Updated
